Hemant Surgical Industries Ltd
BSE:543916
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (83), the stock would be worth ₹-673.97 (324% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -37.1 | ₹301.2 |
0%
|
| Industry Average | 83 | ₹-673.97 |
-324%
|
| Country Average | 49.7 | ₹-404.12 |
-234%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
H
|
Hemant Surgical Industries Ltd
BSE:543916
|
3.9B INR | -37.1 | 48.8 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 12.5 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 19.7 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 19.8 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 6.8 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 40.9 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 21.6 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 8.9 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 136.2 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | -35.6 | 7.2 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 27.4 |
| Median | 49.7 |
| 70th Percentile | 92 |
| Max | 57 010.1 |
Other Multiples
Hemant Surgical Industries Ltd
Glance View
Hemant Surgical Industries Ltd. operates as a pharmaceutical company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2023-06-05. The firm's product offerings cover a spectrum of equipment and disposables required for renal care, cardiovascular disease, respiratory disease, critical care and radiology and surgical disposables. Its range of products includes the indigenously manufactured products along with some other products that are imported from countries, such as Japan, China and France, Australia and are further processed in our assembly units. Its product categories include Aero Healthcare Products, JMS Products, Dialysis Products and Covid Care Products. Its services include home dialysis treatment, home dialysis solution on outright purchase, turnkey dialysis center setup, dialysis center management, dialysis machine on a rental basis, AMC/CMC contract for the dialysis machine and oxygen concentrator on a rental basis.
